Spanish dermatology specialist Almirall has announced positive, top-line results from the pivotal Phase III ADorable-1 trial ...

Swiss pharma giant Novartis late Friday announced today that Cosentyx (secukinumab) received US Food and Drug Administration ...

Taiwan is preparing a four-year pharmaceutical resilience program backed by NT$24 billion ($755 million) to reduce reliance on imported medicines and strengthen domestic manufacturing.

The escalating conflict in the Middle East has moved beyond oil markets and energy security to strike at one of India’s most globally integrated industries: pharmaceuticals.

California, USA based biotech Unnatural Products, which is developing orally-delivered macrocyclic peptides to address ...

A Japan-based biotechnology company developing small-molecule therapeutics targeting protein–protein interactions (PPIs).

Shares of US biotech CytomX Therapeutics’ rocketed 53% to $7.16, after the leader in the field of masked, conditionally activated biologics, today announced positive Phase I expansion data for its ...

The Phase III study FIND-CKD investigating the efficacy and safety of Kerendia (finerenone) versus placebo when added to standard of care in adult patients with non-diabetic chronic kidney disease ...

Sovereign wealth funds once appeared only intermittently in life-science financing. Their money surfaced through venture funds or private equity partnerships, usually at one remove from the operating ...

Europe is achieving better cancer outcomes without cancer overwhelming health budgets, according to the Comparator Report on Cancer in Europe 2025 by the Swedish Institute for Health Economics (IHE).

Under the Medicare Drug Price Negotiation Program (Negotiation Program), the US Centers for Medicare & Medicaid Services (CMS) directly negotiates the prices of certain high expenditure, single source ...

Global drug regulators have continued to move a steady stream of approvals and recommendations through early March, with activity spanning oncology, vaccines, and regulatory policy discussions. The US ...